LFA-9 (mPGES-1/5-LOX Inhibitor): Preclinical Studies to Support a Clinical Trial,
LFA-9(mPGES-1/5-LOX 抑制剂):支持临床试验的临床前研究,
基本信息
- 批准号:10794912
- 负责人:
- 金额:$ 41.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-17 至 2024-03-16
- 项目状态:已结题
- 来源:
- 关键词:APC geneAbdominal PainAdverse effectsAffectAnti-Inflammatory AgentsApcMin/+ miceArachidonate 5-LipoxygenaseAspirinBiological AssayCanis familiarisCardiovascular systemCellsChemopreventionChemopreventive AgentChronicClinical TrialsColonColonic NeoplasmsColorectal CancerCoronary heart diseaseDevelopmentDiarrheaDiseaseDockingDominant Genetic ConditionsDoseDrug KineticsDuodenumEpoprostenolEventFamilial Adenomatous Polyposis SyndromeGene MutationGenesHeadHepatocyteHereditary DiseaseHigh Pressure Liquid ChromatographyHumanIbuprofenIn VitroInflammatoryIntestinal NeoplasmsLeftLipoxygenase InhibitorsMammalian CellMetabolismMethodsMicrosomesMolecularMusMutationNaproxenNervous System PhysiologyOralOral AdministrationPTGS2 genePatientsPrecancerous PolypProstaglandin ProductionProstaglandinsProstaglandins IRattusRecording of previous eventsRecoveryRectumResearch PersonnelRiskRodentSmall Intestinal NeoplasmTechniquesTestingToxic effectWorkadenomaanalogappropriate doseautosomecardiovascular risk factorcelecoxibcolorectal cancer preventioncyclooxygenase 1cytokineefficacy studyin silicoin vivolead candidatelifetime riskmicronucleusnonhuman primatepreclinical studyrectalscreeningside effecttargeted agentthrombotic
项目摘要
Familial Adenomatous Polyposis (FAP) is a rare inherited disease which results from an autosomal dominant genetic alteration in the adenomatous polyposis coli (APC) gene. Patients with this disease develop hundreds to thousands of pre-cancerous polyps (adenomas) in the duodenum, colon and rectum. Left untreated, patients have almost 100% lifetime risk of developing colorectal cancer (CRC).
There is unequivocal evidence of chemopreventive efficacy in CRC with anti-inflammatory agents that exert their effects through COX-2 inhibition (e.g. aspirin, ibuprofen, naproxen and celecoxib), however chronic use of these agents is associated with an increased risk of GI toxicity. Moreover, agents that target COX-2 have been implicated in cardiovascular (CV) and thrombotic events for patients with a baseline history of atherosclerotic heart disease.
Several investigators have shown the increased CV risk to be associated with reduced levels of prostaglandin I2 (PGI2 or prostacyclin) and increased levels of 5-lipoxygenase (5-LOX) metabolites. Hence, Dr. Rao and others hypothesize that agents that spare PGI2 and selectively block production of prostaglandin E-2 (PGE2) and 5-LOX metabolites should prove promising in the prevention of CRC. One such agent, licofelone, targets microsomal prostaglandin E Synthase-1 (mPGES-1) and 5-LOX, and suppresses small intestinal and colonic tumor formation in the ApcMin/+ mouse at doses that are devoid of overt toxicity. Inhibition of intestinal tumors was also associated with decreases in inflammatory cytokines and COX and 5-LOX activities. Furthermore, in clinical trials for OA, the common side effects with licofelone
were mild (abdominal pain and diarrhea).
In silico molecular docking techniques and in vitro and in vivo screening methods have been employed to identify biologically active licofelone analogs. The lead candidate of this effort, LFA- 9, has been selected for further development. The main objective of this Task Order RFP is to conduct preclinical studies with LFA-9 to support its use in a clinical trial.
家族性腺瘤性息肉病(FAP)是一种罕见的遗传性疾病,其起因于大肠腺瘤性息肉病(APC)基因的常染色体显性遗传改变。患有这种疾病的患者在十二指肠、结肠和直肠中形成数百至数千个癌前息肉(腺瘤)。如果不进行治疗,患者几乎有100%的终身风险患结直肠癌(CRC)。
有明确的证据表明,通过抑制考克斯-2发挥作用的抗炎药(例如阿司匹林、布洛芬、萘普生和塞来昔布)对CRC具有化学预防功效,但长期使用这些药物与GI毒性风险增加相关。此外,靶向考克斯-2的药物与基线有动脉粥样硬化性心脏病病史的患者的心血管(CV)和血栓形成事件有关。
几位研究者已经证明CV风险增加与前列腺素I2(PGI 2或前列环素)水平降低和5-脂氧合酶(5-LOX)代谢产物水平升高相关。因此,Rao博士和其他人假设,节省PGI 2并选择性阻断前列腺素E-2(PGE 2)和5-LOX代谢产物产生的药物在预防CRC方面应该是有希望的。一种这样的药剂,licofelone,靶向微粒体前列腺素E合酶-1(mPGES-1)和5-LOX,并且在没有明显毒性的剂量下抑制ApcMin/+小鼠中的小肠和结肠肿瘤形成。肠肿瘤的抑制也与炎性细胞因子和考克斯和5-LOX活性的降低有关。此外,在OA的临床试验中,
轻度(腹痛和腹泻)。
计算机分子对接技术和体外和体内筛选方法已被用于鉴定具有生物活性的利卡非龙类似物。这一努力的主要候选者LFA- 9已被选定用于进一步开发。本任务指令RFP的主要目的是对LFA-9进行临床前研究,以支持其在临床试验中的使用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David McCormick其他文献
David McCormick的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David McCormick', 18)}}的其他基金
LFA-9 (mPGES-1/5-LOX Inhibitor): Preclinical Studies to Support a Clinical Trial,
LFA-9(mPGES-1/5-LOX 抑制剂):支持临床试验的临床前研究,
- 批准号:
10399397 - 财政年份:2018
- 资助金额:
$ 41.87万 - 项目类别:
IGF::OT::IGF NExT Preclinical Toxicology & Pharmacology of Drugs Developed for Cancer Patients, TO#3, Exploratory Studies of CCR4 CART Cells
IGF::OT::IGF NExT 临床前毒理学
- 批准号:
10361380 - 财政年份:2017
- 资助金额:
$ 41.87万 - 项目类别:
Mechanisms of Rapid Modulation of Auditory Responsiveness
听觉反应快速调节机制
- 批准号:
10055961 - 财政年份:2016
- 资助金额:
$ 41.87万 - 项目类别:
Cortical Dynamics and Neural/Behavioral Performance
皮质动力学和神经/行为表现
- 批准号:
10544429 - 财政年份:2016
- 资助金额:
$ 41.87万 - 项目类别:
Cortical Dynamics and Neural/Behavioral Performance
皮质动力学和神经/行为表现
- 批准号:
10530597 - 财政年份:2016
- 资助金额:
$ 41.87万 - 项目类别:
Cortical Dynamics and Neural/Behavioral Performance
皮质动力学和神经/行为表现
- 批准号:
10058278 - 财政年份:2016
- 资助金额:
$ 41.87万 - 项目类别:
Cortical Dynamics and Neural/Behavioral Performance
皮质动力学和神经/行为表现
- 批准号:
10304870 - 财政年份:2016
- 资助金额:
$ 41.87万 - 项目类别:
CALCIUM SIGNALING AND PREFRONTAL DEFICITS IN SCHIZOPHRENIA
精神分裂症的钙信号传导和前额叶缺陷
- 批准号:
7958212 - 财政年份:2009
- 资助金额:
$ 41.87万 - 项目类别:
Properties of Axons and Synaptic Communication in the Neocortex
新皮质中轴突和突触通讯的特性
- 批准号:
7760193 - 财政年份:2008
- 资助金额:
$ 41.87万 - 项目类别:
相似海外基金
Disrupted sleep architecture in adolescents with functional abdominal pain disorders
患有功能性腹痛疾病的青少年的睡眠结构被破坏
- 批准号:
10641146 - 财政年份:2023
- 资助金额:
$ 41.87万 - 项目类别:
Development and Testing of an Intervention to Facilitate Shared Decision-Making in Pediatric Patients with Abdominal Pain Presenting to the Community Emergency Department Setting
开发和测试一种干预措施,以促进社区急诊科就诊的腹痛儿科患者共同决策
- 批准号:
10723374 - 财政年份:2023
- 资助金额:
$ 41.87万 - 项目类别:
Abdominal Pain in Older Patients in Emergency Departments
急诊科老年患者的腹痛
- 批准号:
10739136 - 财政年份:2023
- 资助金额:
$ 41.87万 - 项目类别:
Evaluation of abdominal pain after mucosal healing in patients with inflammatory bowel disease -comprehensive analysis of HPA axis-
炎症性肠病患者黏膜愈合后腹痛评价-HPA轴综合分析-
- 批准号:
22K16013 - 财政年份:2022
- 资助金额:
$ 41.87万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Randomized controlled trial of an internet-based prevention intervention for young children at-risk for functional abdominal pain
针对有功能性腹痛风险的幼儿进行基于互联网的预防干预的随机对照试验
- 批准号:
10387725 - 财政年份:2022
- 资助金额:
$ 41.87万 - 项目类别:
Randomized controlled trial of an internet-based prevention intervention for young children at-risk for functional abdominal pain
针对有功能性腹痛风险的幼儿进行基于互联网的预防干预的随机对照试验
- 批准号:
10608073 - 财政年份:2022
- 资助金额:
$ 41.87万 - 项目类别:
Novel microbial driven histamine pathways underlying chronic abdominal pain
慢性腹痛背后的新型微生物驱动组胺途径
- 批准号:
453255 - 财政年份:2021
- 资助金额:
$ 41.87万 - 项目类别:
Operating Grants
Home-based transcutaneous electrical acustimulation for abdominal pain
家庭经皮电针治疗腹痛
- 批准号:
10619029 - 财政年份:2020
- 资助金额:
$ 41.87万 - 项目类别:
Home-based transcutaneous electrical acustimulation for abdominal pain
家庭经皮电针治疗腹痛
- 批准号:
10045379 - 财政年份:2020
- 资助金额:
$ 41.87万 - 项目类别:
Home-based transcutaneous electrical acustimulation for abdominal pain
家庭经皮电针治疗腹痛
- 批准号:
10685484 - 财政年份:2020
- 资助金额:
$ 41.87万 - 项目类别: